Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane; Junji Furuse; Akira Fukutomi; Tomohisa Iwai; Shoji Nakamori; Ken Kawabe; Kyoko Shimizu; Masato Ozaka; Masafumi Ikeda; Yasushi Kojima; Yasuyuki Kawamoto; Tatsuya Ioka; Hiroaki Yanagimoto; Akinori Asagi; Ken Kamata; Junki Mizusawa; Naoya Kato; Seigo Yukisawa; Hiroki Hara; Makoto Ueno; Hiroshi Ishii; Kazutoshi Tobimatsu; Nobumasa Mizuno; Kazuhiko Shioji; Rie Sugimoto; Naohiro Okano; Kei Yane; Takuji Okusaka; Toshio Nakagohri; Tatsuya Yamashita; Hiroyuki Yamaguchi; Kazuyoshi Nakamura; Keita Wada; Hiroyoshi Miyakawa; Kazuya Sugimori; A. Hosokawa; Hiroshi Katayama

doi:10.1093/annonc/mdz402

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane(Tokyo National Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Akira Fukutomi(Shizuoka Cancer Center), Tomohisa Iwai(Kitasato University Hospital), Shoji Nakamori(Osaka National Hospital), Ken Kawabe(Kyushu University), Kyoko Shimizu(Tokyo Women's Medical University), Masato Ozaka(The Cancer Institute Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Yasushi Kojima(Center for Global Health), Yasuyuki Kawamoto(Hokkaido University Hospital), Tatsuya Ioka(National Cancer Center Hospital East), Hiroaki Yanagimoto(National Cancer Center Hospital East), Akinori Asagi(Shikoku Cancer Center), Ken Kamata(Kindai University), Junki Mizusawa(Japan Clinical Cancer Research Organization), Naoya Kato(The University of Tokyo), Seigo Yukisawa(Tochigi Cancer Center), Hiroki Hara(Saitama Cancer Center), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Hiroshi Ishii(Chiba Cancer Center), Kazutoshi Tobimatsu(Kobe University), Nobumasa Mizuno(Aichi Cancer Center), Kazuhiko Shioji(Niigata Cancer Center Hospital), Rie Sugimoto(National Hospital Organization Kyushu Cancer Center), Naohiro Okano(Kyorin University), Kei Yane(Teine Keijinkai Hospital), Takuji Okusaka(National Cancer Centre Japan), Toshio Nakagohri(Tokai University), Tatsuya Yamashita(Tokyo Metropolitan Police Hospital), Hiroyuki Yamaguchi(Jichi Medical University), Kazuyoshi Nakamura(Chiba Cancer Center), Keita Wada(Teikyo University), Hiroyoshi Miyakawa(Sendai Kousei Hospital), Kazuya Sugimori(National Cancer Center Hospital East), A. Hosokawa(University of Toyama), Hiroshi Katayama(National Cancer Center)

Annals of Oncology

September 26, 2019

10.1093/annonc/mdz402

Cited by 333

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

|NEJM Evidence|2022|1.4k

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

|NEJM Evidence|2022|1.1k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1k

The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

|The Oncologist|2010|977

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

|Nature Genetics|2014|780